Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD
Journal of the American Society of Nephrology · 2026-10 · 37 (10S)
DOI: 10.1681/asn.2026ref7745h ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026-10. Verfasst von Mohammad Abdullah Al Zubair Naim und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Naim, M. A. A. Z., Thomas, F., Streja, E., Davis, R. L., Kalantar-Zadeh, K., Sumida, K., & Kovesdy, C. P. (2026). Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD. Journal of the American Society of Nephrology, 37(10S). https://doi.org/10.1681/asn.2026ref7745h
Vancouver
Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD. Journal of the American Society of Nephrology. 2026;37(10S). doi:10.1681/asn.2026ref7745h
BibTeX
@article{Naim2026,
author = {Naim, Mohammad Abdullah Al Zubair and Thomas, Fridtjof and Streja, Elani and Davis, Robert L. and Kalantar-Zadeh, Kamyar and Sumida, Keiichi and Kovesdy, Csaba P.},
title = {Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {10S},
doi = {10.1681/asn.2026ref7745h}
}
EUVIMED